Financing Cash Flow
Edwards Lifesciences Financing Cash Flow decreased by 3857.9% to -$451.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 74.9%, from -$258.00M to -$451.20M. Over 4 years (FY 2021 to FY 2025), Financing Cash Flow shows a downward trend with a 28.0% CAGR.
Analysis
How to read this metric
A large negative value typically indicates a company is returning capital to shareholders or paying down debt, while a positive value suggests the company is raising external capital to fund operations or acquisitions.
Detailed definition
This metric represents the net flow of cash between a company and its capital providers, including shareholders and lend...
Peer comparison
Large-cap peers like Microsoft or Alphabet similarly show large negative financing outflows due to aggressive share repurchase programs and dividend distributions.
net_cash_from_financingHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$59.00M | $39.00M | -$62.00M | -$368.10M | -$308.10M | -$69.90M | -$838.40M | -$206.60M | $52.10M | -$143.30M | -$413.20M | $61.70M | -$96.60M | -$976.70M | $0.00 | -$258.00M | $52.70M | -$740.10M | -$11.40M | -$451.20M |
| QoQ Change | — | +166.1% | -259.0% | -493.7% | +16.3% | +77.3% | <-999% | +75.4% | +125.2% | -375.0% | -188.3% | +114.9% | -256.6% | -911.1% | +100.0% | — | +120.4% | <-999% | +98.5% | <-999% |
| YoY Change | — | — | — | — | -422.2% | -279.2% | <-999% | +43.9% | +116.9% | -105.0% | +50.7% | +129.9% | -285.4% | -581.6% | +100.0% | -518.2% | +154.6% | +24.2% | — | -74.9% |
Financing Cash Flow at Other Companies
Frequently Asked Questions
- What is Edwards Lifesciences's financing cash flow?
- Edwards Lifesciences (EW) reported financing cash flow of -$451.20M in Q1 2026.
- How has Edwards Lifesciences's financing cash flow changed year-over-year?
- Edwards Lifesciences's financing cash flow decreased by 74.9% year-over-year, from -$258.00M to -$451.20M.
- What is the long-term trend for Edwards Lifesciences's financing cash flow?
- Over 4 years (2021 to 2025), Edwards Lifesciences's financing cash flow has grown at a 28.0% compound annual growth rate (CAGR), from -$356.30M to -$956.80M.
- What does financing cash flow mean?
- The total amount of money a company spends or receives from borrowing debt and managing its own shares and dividends.